global strategic collaboration
Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb
Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials